NUS NYSE Wholesale-Drugs, Proprietaries & Druggists' Sundries Financials FY2016βFY2025
Nu Skin Enterprises, Inc. had $1.5B of revenue in fiscal 2025, down 14.3% on the year before. Over five years, revenue changed β10.5% a year on average.
Last close Β· Oct 23, 2026
$4.79
2.6%Hi! I read Nu Skin Enterprises, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β14.3%
No. Sales fell 14.3% last year.
Does it make a profit?
10.8%
Yes. It keeps 10.8% of every sale as profit.
Does profit turn into cash?
3.1%
Partly. 3.1% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Nu Skin Enterprises, Inc. had $1.5B of revenue in fiscal 2025, down 14.3% on the year before. Over five years, revenue changed β10.5% a year on average. Its operating margin was 4.4%, up 13.2Β pts: of every 100 in sales, about 4 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Nu Skin Enterprises, Inc. made $160M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 2.5% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $46.0M in fiscal 2025, 3.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Nu Skin Enterprises, Inc. returned $31.9M to shareholders in fiscal 2025, 69% of free cash flow. The diluted share count rose 1.3%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $0.1M and sold $0.1M of shares on the open market.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.1M
1 insider
Sold, 12 months
$0.1M
3 insiders
Of sales under plans
82%
$0.1M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | James M WinettDirector | Sold plan | 7,203 | $5.62 | $0.0M | Form 4 |
| Jun 1, 2026 | Edwina D WoodburyDirector | Sold plan | 7,203 | $5.70 | $0.0M | Form 4 |
| May 11, 2026 | Laura NathansonDirector | Sold | 2,676 | $6.73 | $0.0M | Form 4 |
| Nov 11, 2025 | Steven Keith HatchettChief Product Officer | Bought | 5,500 | $9.61 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Nu Skin Enterprises, Inc. has $7.3M more cash than debt.
Cash, debt and the ratios that show how comfortably Nu Skin Enterprises, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $355M | $279M | $268M | $198M | $240M |
| Debt incl. finance leases | $384M | $418M | $516M | $404M | $233M |
| Net debt / EBITDA | 0.1x | 0.8x | 2.1x | β | β0.1x |
| Debt / equity | 0.4x | 0.4x | 0.6x | 0.6x | 0.3x |
| Interest coverage | 21.3x | 8.2x | 1.9x | β5.7x | 4.7x |
| Current ratio | 1.6x | 2.1x | 2.1x | 1.8x | 2.1x |
| Quick ratio | 0.9x | 1.2x | 1.3x | 1.2x | 1.4x |
| Total assets | $1.9B | $1.8B | $1.8B | $1.5B | $1.4B |
| Total liabilities | $994M | $924M | $987M | $817M | $600M |
| Shareholders' equity | $913M | $897M | $822M | $651M | $805M |
| Net debt (β = net cash) | $28.7M | $139M | $248M | $206M | β$7.3M |
KIRA Β· Its return on capital was 6.8%: every 100 invested in the business earned about 7 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Nu Skin Enterprises, Inc. passes 6 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 9 | 5 / 9 | 7 / 9 | 5 / 9 | 5 / 9 | 5 / 9 | 5 / 9 | 5 / 9 | 6 / 9 |
| Accruals ratio | β9.0% | β11.3% | β4.9% | β0.3% | β10.1% | 0.3% | β0.2% | β6.1% | β15.8% | 5.6% |
| Altman Z'' | 6.76 | 6.66 | 6.39 | 6.65 | 6.04 | 6.24 | 6.34 | 5.78 | 5.02 | 7.36 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.2B | $2.3B | $2.7B | $2.4B | $2.6B | $2.7B | $2.2B | $2.0B | $1.7B | $1.5B |
| Gross profit | $1.7B | $1.8B | $2.0B | $1.8B | $1.9B | $2.0B | $1.6B | $1.4B | $1.2B | $1.0B |
| Research and development | $24.3M | $22.0M | $23.0M | $30.1M | $23.3M | $27.2M | $23.3M | $22.6M | $13.0M | $10.8M |
| Operating income | $231M | $274M | $241M | $267M | $258M | $234M | $111M | $48.3M | β$152M | $65.8M |
| Interest expense | $15.6M | $22.2M | $21.8M | $19.2M | $13.1M | $11.0M | $13.5M | $25.6M | $26.4M | $13.9M |
| Pretax income | $213M | $266M | $220M | $255M | $256M | $232M | $89.0M | $26.6M | β$175M | $196M |
| Income tax | $69.8M | $136M | $97.8M | $81.6M | $64.9M | $85.2M | β$15.8M | $18.0M | β$28.5M | $36.0M |
| Net income | $143M | $129M | $122M | $174M | $191M | $147M | $105M | $8.6M | β$147M | $160M |
| Diluted EPS | $2.55 | $2.36 | $2.16 | $3.10 | $3.63 | $2.86 | $2.07 | $0.17 | β$2.95 | $3.18 |
| Diluted shares | 0.06B | 0.05B | 0.06B | 0.06B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | $275M | $303M | $203M | $178M | $379M | $142M | $108M | $119M | $112M | $80.3M |
| Capital expenditure | $50.2M | $60.2M | $70.4M | $66.1M | $63.8M | $68.6M | $59.1M | $58.5M | $41.6M | $34.3M |
| Free cash flow | $225M | $242M | $132M | $112M | $315M | $73.0M | $49.0M | $60.1M | $70.2M | $46.0M |
| Depreciation and amortization | $72.4M | $71.6M | $83.0M | $76.7M | $74.0M | $76.3M | $72.5M | $70.9M | $69.8M | $52.3M |
| Stock-based compensation | $8.9M | $19.3M | $26.6M | $9.9M | $24.1M | $23.2M | $12.4M | $15.6M | $14.8M | $24.1M |
| Acquisitions | β | $31.7M | $38.5M | $8.1M | $14.9M | $19.0M | $0.0M | $77.3M | $0.0M | $0.0M |
| Share buybacks | $247M | $71.7M | $69.6M | $0.8M | $144M | $80.4M | $70.0M | $13.0M | $0.0M | $20.0M |
| Dividends paid | $78.4M | $76.1M | $80.6M | $82.2M | $78.4M | $76.3M | $77.0M | $77.6M | $11.9M | $11.8M |
| Dividends and buybacks | $326M | $148M | $150M | $83.0M | $223M | $157M | $147M | $90.6M | $11.9M | $31.9M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $368M | $438M | $398M | $344M | $424M | $355M | $279M | $268M | $198M | $240M |
| Total debt | $417M | $389M | $430M | $362M | $335M | $376M | $402M | $503M | $394M | $224M |
| Finance lease liabilities | β | β | β | β | $9.7M | $7.3M | $15.5M | $12.7M | $10.2M | $8.4M |
| Current assets | $714M | $778M | $799M | $740M | $903M | $873M | $760M | $702M | $539M | $548M |
| Current liabilities | $399M | $447M | $440M | $357M | $543M | $530M | $359M | $329M | $297M | $264M |
| Inventory | $250M | $253M | $296M | $276M | $314M | $400M | $346M | $280M | $190M | $179M |
| Property and equipment, net | $445M | $465M | $465M | $454M | $468M | $454M | $445M | $433M | $380M | $377M |
| Goodwill | $115M | $115M | $197M | $197M | $203M | $206M | $206M | $218M | $83.6M | $83.6M |
| Intangible assets | $63.6M | $67.6M | $90.0M | $80.3M | $89.5M | $77.0M | $66.7M | $95.3M | $74.3M | $42.6M |
| Total assets | $1.5B | $1.6B | $1.7B | $1.8B | $2.0B | $1.9B | $1.8B | $1.8B | $1.5B | $1.4B |
| Total liabilities | $810M | $885M | $913M | $894M | $1.1B | $994M | $924M | $987M | $817M | $600M |
| Shareholders' equity | $664M | $705M | $782M | $875M | $894M | $913M | $897M | $822M | $651M | $805M |
| Margins | ||||||||||
| Gross margin | 77.3% | 78.0% | 76.3% | 76.0% | 74.5% | 75.0% | 71.7% | 68.9% | 68.2% | 69.4% |
| Operating margin | 10.5% | 12.0% | 9.0% | 11.0% | 10.0% | 8.7% | 5.0% | 2.5% | β8.8% | 4.4% |
| EBITDA margin | 13.7% | 15.2% | 12.1% | 14.2% | 12.8% | 11.5% | 8.2% | 6.1% | β4.7% | 7.9% |
| Net margin | 6.5% | 5.7% | 4.5% | 7.2% | 7.4% | 5.5% | 4.7% | 0.4% | β8.5% | 10.8% |
| FCF margin | 10.2% | 10.6% | 4.9% | 4.6% | 12.2% | 2.7% | 2.2% | 3.1% | 4.1% | 3.1% |
| Returns | ||||||||||
| Return on capital | 21.8% | 27.2% | 19.2% | 20.4% | 23.9% | 16.3% | 10.9% | 3.0% | β14.1% | 6.8% |
| Return on capital employed | 21.5% | 24.0% | 19.2% | 18.9% | 18.2% | 17.0% | 7.6% | 3.3% | β12.9% | 5.8% |
| Return on equity | 21.5% | 18.9% | 16.4% | 20.9% | 21.6% | 16.3% | 11.6% | 1.0% | β19.9% | 22.0% |
| Return on assets | 9.7% | 8.4% | 7.4% | 10.0% | 10.3% | 7.6% | 5.6% | 0.5% | β8.9% | 11.1% |
| Return on tangible equity | 29.5% | 24.8% | 24.6% | 29.0% | 31.8% | 23.4% | 16.8% | 1.7% | β29.7% | 23.6% |
| Growth | ||||||||||
| Revenue growth | β | 3.2% | 17.5% | β9.7% | 6.7% | 4.4% | β17.4% | β11.5% | β12.0% | β14.3% |
| Net income growth | β | β9.5% | β5.8% | 42.4% | 10.3% | β23.0% | β28.9% | β91.8% | β1,805.6% | β |
| EPS growth | β | β7.5% | β8.5% | 43.5% | 17.1% | β21.2% | β27.6% | β91.8% | β1,835.3% | β |
| FCF growth | β | 7.7% | β45.4% | β15.5% | 181.9% | β76.9% | β32.8% | 22.7% | 16.6% | β34.4% |
| Share count change | β | β2.2% | 3.0% | β1.0% | β5.7% | β2.5% | β1.8% | β1.3% | β0.4% | 1.3% |
| Financial health | ||||||||||
| Net debt / EBITDA | 0.2x | β0.1x | 0.1x | 0.1x | β0.2x | 0.1x | 0.8x | 2.1x | β | β0.1x |
| Debt / equity | 0.6x | 0.6x | 0.6x | 0.4x | 0.4x | 0.4x | 0.4x | 0.6x | 0.6x | 0.3x |
| Interest coverage | 14.8x | 12.4x | 11.0x | 13.9x | 19.7x | 21.3x | 8.2x | 1.9x | β5.7x | 4.7x |
| Current ratio | 1.8x | 1.7x | 1.8x | 2.1x | 1.7x | 1.6x | 2.1x | 2.1x | 1.8x | 2.1x |
| Quick ratio | 1.2x | 1.2x | 1.1x | 1.3x | 1.1x | 0.9x | 1.2x | 1.3x | 1.2x | 1.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.3% | 2.6% | 2.6% | 2.7% | 2.5% | 2.5% | 2.7% | 3.0% | 2.4% | 2.3% |
| Stock comp / revenue | 0.4% | 0.8% | 1.0% | 0.4% | 0.9% | 0.9% | 0.6% | 0.8% | 0.9% | 1.6% |
| Payouts / FCF | 144.7% | 61.0% | 113.4% | 74.2% | 70.6% | 214.7% | 300.1% | 150.7% | 17.0% | 69.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 5.0 | 7.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 6.0 |
| Altman Z'' | 6.8 | 6.7 | 6.4 | 6.7 | 6.0 | 6.2 | 6.3 | 5.8 | 5.0 | 7.4 |
| Accruals ratio | β9.0% | β11.3% | β4.9% | β0.3% | β10.1% | 0.3% | β0.2% | β6.1% | β15.8% | 5.6% |
Source: SEC EDGAR XBRL filings (CIK 0001021561). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
